Clarification Needed: Question Does Not Match Available Evidence
The question asks about differences between old and new guidelines for managing diabetic ketoacidosis (DKA), but the provided evidence does not contain any formal clinical practice guidelines specifically addressing DKA management protocols.
What the Evidence Actually Contains
The available evidence includes:
- Kidney disease guidelines: KDOQI/KDIGO guidelines for CKD evaluation, nutrition, and diabetes management in CKD patients 1
- Research reviews on DKA: General discussions of controversies and treatment challenges in DKA management, but these are not formal guidelines 2, 3, 4, 5, 6
Key Limitation
No formal DKA-specific clinical practice guidelines (old or new) are present in the evidence provided. The research articles mention that DKA management has controversies and that "different society guidelines have inconsistencies in their recommendations" 5, and note that "many aspects of DKA management are currently based on low-quality evidence" 2, but they do not present the actual guideline recommendations or compare versions.
What Can Be Addressed
If your question is actually about:
- CKD guideline updates: The evidence shows evolution from 2002 KDOQI to 2012 KDIGO to 2024 KDIGO guidelines, with major changes including addition of albuminuria staging, race-free eGFR equations, and new pharmacologic therapies 1
- Diabetes management in CKD: The 2020 and 2022 KDIGO guidelines introduced SGLT2 inhibitors and GLP-1 receptor agonists as cornerstone therapies 1, 7
Please clarify which specific guideline comparison you are seeking.